GRI Bio (GRI)
Nasdaq Market Closed
GRI Bio, Inc. is a clinical-stage biotechnology company developing therapies for serious diseases in which the immune system is abnormally activated. The company focuses on inflammatory, fibrotic, and autoimmune conditions, where dysregulated immune responses can drive tissue damage and long-term disease progression. Its strategy centres on modulating Natural Killer T, or NKT, cells, a class of immune cells that can influence both inflammatory signalling and immune balance.
GRI Bio’s lead programme is GRI-0621, an oral small-molecule candidate designed as a dual agonist of retinoic acid receptor beta and gamma. The company is evaluating the compound for its ability to inhibit human type 1 NKT cell activity and help restore immune homeostasis. The active approach is related to tazarotene, a synthetic retinoid best known for dermatology uses such as psoriasis and acne, but GRI Bio is pursuing systemic applications in diseases where immune-driven inflammation and fibrosis are central features.
The company is also advancing GRI-0803, an oral candidate intended to activate type 2 NKT cells. This programme is aimed at autoimmune disorders and reflects GRI Bio’s broader interest in selectively adjusting immune pathways rather than broadly suppressing immunity. As a development-stage biotech, GRI Bio’s value is closely tied to preclinical and clinical progress, regulatory milestones, safety data, and its ability to secure capital or partnerships. Investors typically view the stock as a high-risk life sciences exposure, with potential upside linked to successful validation of its NKT cell-focused platform.
Last updated
- Market Cap
- 4.09M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- -6.96M
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 4.09M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -6.96M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.39
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.64
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -6.16
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -12.14M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -103.44%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -96.2%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 14.21
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 14.21
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 13.91
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 45.78K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 2.31
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -2M | -2.66M | -3.37M | -2.9M | -3.05M |
| EBITDA | -2M | -2.66M | -3.36M | -2.9M | -3.05M |
| Net income | -2M | -2.66M | -3.36M | -2.89M | -3.05M |
| Basic EPS | -1.61 | -116.61 | -1.28 | -1.31 | -162.3 |
| Diluted EPS | -1.61 | -116.61 | -1.28 | -1.31 | -162.3 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 11.34M | 8.67M | 4.78M | 5.68M | 4.04M |
| Total liabilities | 794K | 2.66M | 2.79M | 2.35M | 2.84M |
| Total equity | 10.55M | 6.01M | 1.99M | 3.32M | 1.21M |
| Cash & equivalents | 11.05M | 8.23M | 4.06M | 5.12M | 3.28M |
| Current assets | 11.28M | 8.59M | 4.7M | 5.58M | 3.93M |
| Current liabilities | 794K | 2.64M | 2.76M | 2.31M | 2.78M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -3.69M | -2.97M | -2.31M | -3.17M | -1.74M |
| Investing cash flow | — | -3K | — | — | — |
| Financing cash flow | 6.5M | 7.15M | 1.25M | 5.01M | -11K |
| Change in cash | 2.82M | 4.17M | -1.07M | 1.84M | -1.75M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — GRI Bio, Inc. | View Filing | |
| edgar index | 10-Q — GRI Bio, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — GRI Bio, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | UPLOAD — GRI Bio, Inc. | View Filing | |
| edgar index | S-8 — GRI Bio, Inc. | View Filing | |
| edgar index | S-3 — GRI Bio, Inc. | View Filing | |
| edgar index | 424B5 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 10-K — GRI Bio, Inc. | View Filing | |
| edgar index | CORRESP — GRI Bio, Inc. | View Filing | |
| edgar index | EFFECT — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — GRI Bio, Inc. | View Filing | |
| edgar index | DEF 14A — GRI Bio, Inc. | View Filing | |
| edgar index | PRE 14A — GRI Bio, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 424B4 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | EFFECT — GRI Bio, Inc. | View Filing | |
| edgar index | S-1/A — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | CORRESP — GRI Bio, Inc. | View Filing | |
| edgar index | CORRESP — GRI Bio, Inc. | View Filing | |
| edgar index | S-1 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 424B3 — GRI Bio, Inc. | View Filing | |
| edgar index | 8-K — GRI Bio, Inc. | View Filing | |
| edgar index | 10-Q — GRI Bio, Inc. | View Filing | |
| edgar index | 424B3 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| form 4 | Form 4 — Kelly Leanne | View Filing | |
| form 4 | Form 4 — Szekeres David Leslie | View Filing | |
| form 4 | Form 4 — Rongen Roelof | View Filing | |
| form 4 | Form 4 — SIMPSON CAMILLA V | View Filing | |
| form 4 | Form 4 — Baker David Charles | View Filing | |
| form 4 | Form 4 — Hertz Walter Marc | View Filing | |
| form 4 | Form 4 — Chaturvedi Vipin | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| edgar index | 4 — GRI Bio, Inc. | View Filing | |
| form 4 | Form 4 — Kelly Leanne | View Filing | |
| form 4 | Form 4 — SIMPSON CAMILLA V | View Filing | |
| form 4 | Form 4 — Chaturvedi Vipin | View Filing |